Amgad Mentias1, Saket Girotra2, Milind Y Desai3, Phillip A Horwitz2, James D Rossen2, Marwan Saad4, Sidakpal Panaich2, Samir Kapadia3, Mary Vaughan Sarrazin5. 1. Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa. Electronic address: amgad-mentias@uiowa.edu. 2. Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa. 3. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 4. Cardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Department of Cardiology, Ain Shams University, Cairo, Egypt. 5. Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa; Comprehensive Access and Delivery Research and Evaluation Center, Iowa City VA Medical Center, Iowa City, Iowa.
Abstract
OBJECTIVES: This study sought to evaluate the incidence and outcomes of endocarditis after transcatheter aortic valve replacement (TAVR). BACKGROUND: Data about endocarditis after TAVR are limited. METHODS: The study investigated Medicare patients who underwent TAVR from 2012 to 2017 and identified patients admitted with endocarditis during follow-up using a validated algorithm. The main study outcome was all-cause mortality. RESULTS: Of 134,717 patients who underwent TAVR, 1868 patients developed endocarditis during follow-up (incidence 0.87%/year), with majority of infections (65.0%) occurring within 1 year. Incidence of endocarditis declined in recent years. The most common organisms were Staphylococcus (22.0%), Streptococcus (20.0%), and Enterococcus (15.5%). Important predictors for endocarditis were younger age at TAVR, male sex, prior endocarditis, end-stage renal disease, repeat TAVR procedures, liver and lung disease, and post-TAVR acute kidney injury. Thirty-day and 1-year mortality were 18.5% and 45.6%, respectively. After adjusting for comorbidities and procedural complications, endocarditis after TAVR was associated with 3-fold higher risk of mortality (44.9 vs. 16.2 deaths per 100 person-years; adjusted hazard ratio [aHR]: 2.94; 95% confidence interval [CI]: 2.77 to 3.12; p < 0.0001). End-stage renal disease (aHR: 2.12; 95% CI: 1.72 to 2.60), endocarditis complicated by cardiogenic shock (aHR: 2.50, 95% CI: 1.56 to 4.02), ischemic stroke (aHR: 1.56; 95% CI: 1.07 to 2.28), intracerebral hemorrhage (aHR: 1.67; 95% CI: 1.01 to 2.76), acute kidney injury (aHR: 1.44; 95% CI: 1.27 to 1.63), blood transfusion (aHR: 1.28; 95% CI: 1.09 to 1.50), staphylococcal (aHR: 1.71; 95% CI: 1.49 to 1.97), and fungal endocarditis (aHR: 1.72; 95% CI: 1.23 to 2.39) (p < 0.05 for all) portended higher mortality following endocarditis. CONCLUSIONS: The incidence of endocarditis after TAVR is low and declining. However, it is associated with poor prognosis with one-half the patients dying within 1 year.
OBJECTIVES: This study sought to evaluate the incidence and outcomes of endocarditis after transcatheter aortic valve replacement (TAVR). BACKGROUND: Data about endocarditis after TAVR are limited. METHODS: The study investigated Medicare patients who underwent TAVR from 2012 to 2017 and identified patients admitted with endocarditis during follow-up using a validated algorithm. The main study outcome was all-cause mortality. RESULTS: Of 134,717 patients who underwent TAVR, 1868 patients developed endocarditis during follow-up (incidence 0.87%/year), with majority of infections (65.0%) occurring within 1 year. Incidence of endocarditis declined in recent years. The most common organisms were Staphylococcus (22.0%), Streptococcus (20.0%), and Enterococcus (15.5%). Important predictors for endocarditis were younger age at TAVR, male sex, prior endocarditis, end-stage renal disease, repeat TAVR procedures, liver and lung disease, and post-TAVR acute kidney injury. Thirty-day and 1-year mortality were 18.5% and 45.6%, respectively. After adjusting for comorbidities and procedural complications, endocarditis after TAVR was associated with 3-fold higher risk of mortality (44.9 vs. 16.2 deaths per 100 person-years; adjusted hazard ratio [aHR]: 2.94; 95% confidence interval [CI]: 2.77 to 3.12; p < 0.0001). End-stage renal disease (aHR: 2.12; 95% CI: 1.72 to 2.60), endocarditis complicated by cardiogenic shock (aHR: 2.50, 95% CI: 1.56 to 4.02), ischemic stroke (aHR: 1.56; 95% CI: 1.07 to 2.28), intracerebral hemorrhage (aHR: 1.67; 95% CI: 1.01 to 2.76), acute kidney injury (aHR: 1.44; 95% CI: 1.27 to 1.63), blood transfusion (aHR: 1.28; 95% CI: 1.09 to 1.50), staphylococcal (aHR: 1.71; 95% CI: 1.49 to 1.97), and fungal endocarditis (aHR: 1.72; 95% CI: 1.23 to 2.39) (p < 0.05 for all) portended higher mortality following endocarditis. CONCLUSIONS: The incidence of endocarditis after TAVR is low and declining. However, it is associated with poor prognosis with one-half the patients dying within 1 year.
Authors: Niels Thue Olsen; Ole De Backer; Hans G H Thyregod; Niels Vejlstrup; Henning Bundgaard; Lars Søndergaard; Nikolaj Ihlemann Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Noriaki Moriyama; Teemu Laakso; Fausto Biancari; Peter Raivio; Maina P Jalava; Jussi Jaakkola; Sebastian Dahlbacka; Eeva-Maija Kinnunen; Tatu Juvonen; Annastiina Husso; Matti Niemelä; Tuomas Ahvenvaara; Tuomas Tauriainen; Marko Virtanen; Pasi Maaranen; Markku Eskola; Stefano Rosato; Timo Mäkikallio; Mikko Savontaus; Antti Valtola; Vesa Anttila; Juhani Airaksinen; Mika Laine Journal: EuroIntervention Date: 2019-08-09 Impact factor: 6.534
Authors: Jennifer M Boland; Heath H Chung; Frans J L Robberts; Walter R Wilson; James M Steckelberg; Larry M Baddour; Dylan V Miller Journal: Mycoses Date: 2010-04-06 Impact factor: 4.377
Authors: Ander Regueiro; Axel Linke; Azeem Latib; Nikolaj Ihlemann; Marina Urena; Thomas Walther; Oliver Husser; Howard C Herrmann; Luis Nombela-Franco; Asim N Cheema; Hervé Le Breton; Stefan Stortecky; Samir Kapadia; Antonio L Bartorelli; Jan Malte Sinning; Ignacio Amat-Santos; Antonio Munoz-Garcia; Stamatios Lerakis; Enrique Gutiérrez-Ibanes; Mohamed Abdel-Wahab; Didier Tchetche; Luca Testa; Helene Eltchaninoff; Ugolino Livi; Juan Carlos Castillo; Hasan Jilaihawi; John G Webb; Marco Barbanti; Susheel Kodali; Fabio S de Brito; Henrique B Ribeiro; Antonio Miceli; Claudia Fiorina; Guglielmo Mario Actis Dato; Francesco Rosato; Vicenç Serra; Jean-Bernard Masson; Harindra C Wijeysundera; Jose A Mangione; Maria-Cristina Ferreira; Valter C Lima; Luiz A Carvalho; Alexandre Abizaid; Marcos A Marino; Vinicius Esteves; Julio C M Andrea; Francesco Giannini; David Messika-Zeitoun; Dominique Himbert; Won-Keun Kim; Costanza Pellegrini; Vincent Auffret; Fabian Nietlispach; Thomas Pilgrim; Eric Durand; John Lisko; Raj R Makkar; Pedro A Lemos; Martin B Leon; Rishi Puri; Alberto San Roman; Alec Vahanian; Lars Søndergaard; Norman Mangner; Josep Rodés-Cabau Journal: JAMA Date: 2016-09-13 Impact factor: 56.272
Authors: Ignacio J Amat-Santos; David Messika-Zeitoun; Helene Eltchaninoff; Samir Kapadia; Stamatios Lerakis; Asim N Cheema; Enrique Gutiérrez-Ibanes; Antonio J Munoz-Garcia; Manuel Pan; John G Webb; Howard C Herrmann; Susheel Kodali; Luis Nombela-Franco; Corrado Tamburino; Hasan Jilaihawi; Jean-Bernard Masson; Fabio Sandoli de Brito; Maria Cristina Ferreira; Valter Correa Lima; José Armando Mangione; Bernard Iung; Alec Vahanian; Eric Durand; E Murat Tuzcu; Salim S Hayek; Rocio Angulo-Llanos; Juan J Gómez-Doblas; Juan Carlos Castillo; Danny Dvir; Martin B Leon; Eulogio Garcia; Javier Cobiella; Isidre Vilacosta; Marco Barbanti; Raj R Makkar; Henrique Barbosa Ribeiro; Marina Urena; Eric Dumont; Philippe Pibarot; Javier Lopez; Alberto San Roman; Josep Rodés-Cabau Journal: Circulation Date: 2015-03-09 Impact factor: 29.690
Authors: Hannah L F Cooper; Joanne E Brady; Daniel Ciccarone; Barbara Tempalski; Karla Gostnell; Samuel R Friedman Journal: Clin Infect Dis Date: 2007-09-25 Impact factor: 9.079
Authors: Norman Mangner; Sergey Leontyev; Felix J Woitek; Philipp Kiefer; Stephan Haussig; Christian Binner; Meinhard Mende; Florian Schlotter; Georg Stachel; Robert Höllriegel; Jennifer Hommel; Katrin Binner-Oussenek; Martin Misfeld; Holger Thiele; Michael A Borger; David Holzhey; Axel Linke Journal: J Am Heart Assoc Date: 2018-09-04 Impact factor: 5.501